Hofseth Biocare ASA (HBC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hofseth Biocare ASA (HBC) has a cash flow conversion efficiency ratio of 0.167x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-4.65 Million ≈ $-489.52K USD) by net assets (Nkr-27.85 Million ≈ $-2.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Hofseth Biocare ASA's balance sheet to measure how much of total assets are equity-financed.
Hofseth Biocare ASA - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Hofseth Biocare ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HBC cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Hofseth Biocare ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hofseth Biocare ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ravad Ltd
TA:RAVD
|
-0.007x |
|
Impulse Fitness Solutions SA
PA:MLIFS
|
N/A |
|
Taeyang Metal
KO:004100
|
0.052x |
|
Raonsecure Co. Ltd
KQ:042510
|
-0.015x |
|
Cheche Group Inc. Class A Ordinary Shares
NASDAQ:CCG
|
-0.012x |
|
U-Best Polymer Industry Co Ltd
TWO:4714
|
0.024x |
|
BEST Inc
NYSE:BEST
|
0.599x |
|
Thunderbird Entertainment Group Inc
V:TBRD
|
-0.099x |
Annual Cash Flow Conversion Efficiency for Hofseth Biocare ASA (2010–2024)
The table below shows the annual cash flow conversion efficiency of Hofseth Biocare ASA from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Hofseth Biocare ASA worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr61.30 Million ≈ $6.45 Million |
Nkr-9.78 Million ≈ $-1.03 Million |
-0.160x | -337.71% |
| 2023-12-31 | Nkr41.14 Million ≈ $4.33 Million |
Nkr2.76 Million ≈ $290.54K |
0.067x | +121.99% |
| 2022-12-31 | Nkr148.03 Million ≈ $15.58 Million |
Nkr-45.17 Million ≈ $-4.75 Million |
-0.305x | +30.67% |
| 2021-12-31 | Nkr140.38 Million ≈ $14.77 Million |
Nkr-61.78 Million ≈ $-6.50 Million |
-0.440x | -88.34% |
| 2020-12-31 | Nkr263.76 Million ≈ $27.76 Million |
Nkr-61.63 Million ≈ $-6.49 Million |
-0.234x | +11.42% |
| 2019-12-31 | Nkr117.75 Million ≈ $12.39 Million |
Nkr-31.06 Million ≈ $-3.27 Million |
-0.264x | +20.71% |
| 2018-12-31 | Nkr86.04 Million ≈ $9.05 Million |
Nkr-28.62 Million ≈ $-3.01 Million |
-0.333x | +51.59% |
| 2017-12-31 | Nkr37.08 Million ≈ $3.90 Million |
Nkr-25.48 Million ≈ $-2.68 Million |
-0.687x | +45.24% |
| 2016-12-31 | Nkr53.56 Million ≈ $5.64 Million |
Nkr-67.23 Million ≈ $-7.07 Million |
-1.255x | -612.71% |
| 2015-12-31 | Nkr32.55 Million ≈ $3.42 Million |
Nkr7.97 Million ≈ $838.36K |
0.245x | +131.04% |
| 2014-12-31 | Nkr78.95 Million ≈ $8.31 Million |
Nkr-62.26 Million ≈ $-6.55 Million |
-0.789x | +41.55% |
| 2013-12-31 | Nkr62.00 Million ≈ $6.52 Million |
Nkr-83.65 Million ≈ $-8.80 Million |
-1.349x | -34.11% |
| 2012-12-31 | Nkr47.72 Million ≈ $5.02 Million |
Nkr-48.01 Million ≈ $-5.05 Million |
-1.006x | -522.78% |
| 2011-12-31 | Nkr120.53 Million ≈ $12.68 Million |
Nkr-19.47 Million ≈ $-2.05 Million |
-0.162x | +1.39% |
| 2010-12-31 | Nkr75.97 Million ≈ $7.99 Million |
Nkr-12.45 Million ≈ $-1.31 Million |
-0.164x | -- |
About Hofseth Biocare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a salmon oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are ca… Read more